JP2020500864A - 経口トリデカン酸テストステロン療法 - Google Patents

経口トリデカン酸テストステロン療法 Download PDF

Info

Publication number
JP2020500864A
JP2020500864A JP2019528756A JP2019528756A JP2020500864A JP 2020500864 A JP2020500864 A JP 2020500864A JP 2019528756 A JP2019528756 A JP 2019528756A JP 2019528756 A JP2019528756 A JP 2019528756A JP 2020500864 A JP2020500864 A JP 2020500864A
Authority
JP
Japan
Prior art keywords
fixed dose
testosterone
administering
method comprises
provides
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019528756A
Other languages
English (en)
Japanese (ja)
Other versions
JP2020500864A5 (enExample
Inventor
チダムバラム，ナチアッパン
クマール ナチャエガリ，サティッシュ
クマール ナチャエガリ，サティッシュ
ブイ． パテル，マヘシュ
ブイ． パテル，マヘシュ
キム，キルヤング
Original Assignee
リポカイン インコーポレーテッド
リポカイン インコーポレーテッド
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by リポカイン インコーポレーテッド, リポカイン インコーポレーテッド filed Critical リポカイン インコーポレーテッド
Publication of JP2020500864A publication Critical patent/JP2020500864A/ja
Publication of JP2020500864A5 publication Critical patent/JP2020500864A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A61K31/568—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol substituted in positions 10 and 13 by a chain having at least one carbon atom, e.g. androstanes, e.g. testosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Endocrinology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Physiology (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
JP2019528756A 2016-11-30 2017-11-30 経口トリデカン酸テストステロン療法 Pending JP2020500864A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662428167P 2016-11-30 2016-11-30
US201662428317P 2016-11-30 2016-11-30
US62/428,317 2016-11-30
US62/428,167 2016-11-30
PCT/US2017/064083 WO2018102618A1 (en) 2016-11-30 2017-11-30 Oral testosterone tridecanoate therapy

Publications (2)

Publication Number Publication Date
JP2020500864A true JP2020500864A (ja) 2020-01-16
JP2020500864A5 JP2020500864A5 (enExample) 2021-11-11

Family

ID=62240656

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019528756A Pending JP2020500864A (ja) 2016-11-30 2017-11-30 経口トリデカン酸テストステロン療法

Country Status (6)

Country Link
US (6) US20180153905A1 (enExample)
EP (1) EP3548037B1 (enExample)
JP (1) JP2020500864A (enExample)
CA (1) CA3078724A1 (enExample)
ES (1) ES2983643T3 (enExample)
WO (1) WO2018102618A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8492369B2 (en) 2010-04-12 2013-07-23 Clarus Therapeutics Inc Oral testosterone ester formulations and methods of treating testosterone deficiency comprising same
JP5887044B2 (ja) 2005-04-15 2016-03-16 クラルス セラピューティクス, インコーポレーテッドClarus Therapeutic, Inc. 疎水性薬物のドラッグデリバリーシステムとその組成物
CA3078724A1 (en) 2016-11-30 2018-06-07 Nachiappan Chidambaram Oral testosterone tridecanoate therapy
WO2020018974A1 (en) * 2018-07-20 2020-01-23 Lipocine Inc. Liver disease
US11931367B2 (en) 2021-09-30 2024-03-19 Lipocine Inc. Oral (17-ß)-3-oxoandrost-4-en-17-yl tridecanoate therapy
US12257257B2 (en) 2023-07-27 2025-03-25 Lipocine, Inc. Testosterone dodecanoate compositions and methods

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016514706A (ja) * 2013-03-15 2016-05-23 リポカイン インコーポレーテッド 経口送達用リポバランス長鎖テストステロンエステル

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20140288039A1 (en) 2009-01-08 2014-09-25 Lipocine Inc. Lipobalanced long chain testosterone prodrugs for oral delivery
US20130225544A1 (en) * 2009-01-08 2013-08-29 Lipocine Inc. Lipobalanced long chain testosterone esters for oral delivery
US10245273B2 (en) 2013-12-26 2019-04-02 Clarus Therapeutics, Inc. Oral pharmaceutical products and methods of use combining testosterone esters with hypolipidemic agents
BR112017004127B1 (pt) 2014-08-28 2023-04-11 Lipocine Inc Composição farmacêutica oral
CA3078724A1 (en) * 2016-11-30 2018-06-07 Nachiappan Chidambaram Oral testosterone tridecanoate therapy

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2016514706A (ja) * 2013-03-15 2016-05-23 リポカイン インコーポレーテッド 経口送達用リポバランス長鎖テストステロンエステル

Also Published As

Publication number Publication date
US11672807B1 (en) 2023-06-13
US10881670B2 (en) 2021-01-05
US12161651B1 (en) 2024-12-10
EP3548037A1 (en) 2019-10-09
EP3548037B1 (en) 2024-07-03
US20200222426A1 (en) 2020-07-16
CA3078724A1 (en) 2018-06-07
US11992496B1 (en) 2024-05-28
ES2983643T3 (es) 2024-10-24
US12303517B1 (en) 2025-05-20
US20180153905A1 (en) 2018-06-07
WO2018102618A1 (en) 2018-06-07
EP3548037A4 (en) 2020-07-29

Similar Documents

Publication Publication Date Title
JP2020503269A (ja) 経口ウンデカン酸テストステロン療法
JP2020500864A (ja) 経口トリデカン酸テストステロン療法
US20200316093A1 (en) Abiraterone acetate lipid formulations
EP2861072B1 (en) Natural combination hormone replacement formulations and therapies
US12011503B1 (en) Fixed dose oral testosterone undecanoate compositions and use thereof
US11123351B2 (en) Pharmaceutical formulation of 3-alpha-ethynyl-3-beta-hydroxyandrostan-17-one oxime
JP6307711B2 (ja) 経口送達用リポバランス長鎖テストステロンエステル
RU2779262C2 (ru) ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ 3α-ЭТИНИЛ-3β-ГИДРОКСИАНДРОСТАН-17-ОНА ОКСИМА
KR101968754B1 (ko) 두타스테라이드 및 탐수로신 함유 경질 캡슐 복합제 및 그 제조방법
WO2018132725A1 (en) Opioid agonist / antagonist combination dosage forms

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201130

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20201130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20210924

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20211130

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20220622